PharmEasy-owned diagnostics lab chain Thyrocare’s consolidated net profit jumped 48.1% to INR 28.1 Cr in Q3 FY26 from INR 19 Cr in the same quarter last year. However, profit declined 41.4% sequentially from INR 47.8 Cr. Revenue from operations grew 17.8% to INR 195.5 Cr from INR 165.9 Cr in Q3 FY25. On a QoQ basis, it declined 9.7% from INR 216.5 Cr. Including other income of INR 5 Cr, total income stood at INR 200.5 Cr during the quarter under review. Meanwhile, total expenses for the period stood at INR 159.2 Cr, up 12.2% from INR 141.9 Cr in the year-ago period. The company also incurred an exceptional cost of INR 5.9 Cr related to one-time labour wage code adjustments and bonus issuance. Thyrocare’s EBITDA rose 38% YoY to INR 57.6 Cr, while normalised EBITDA (excluding non-cash ESOP costs from parent API Holdings) increased 26% YoY to INR 62.2 Cr. EBITDA margin improved to 29% on a reported basis and 32% on a normalised basis from 25% and 30%, respectively, in the year-ago quarter. The company attributed margin expansion to operating leverage, higher pathology volumes, and improved gross margin, which expanded by over 300 basis points YoY to 76%… Read MoreInc42 Media
